Evidence map›Paper›PMID 31790196›Full record

ArticleAnalytical chemistry2020

Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS.

Céline Vocat, Marielle Dunand, Scott A Hubers, Nicolas Bourdillon, Grégoire P Millet, Nancy J Brown, Grégoire Wuerzner, Eric Grouzmann, Philippe J Eugster

Open access · greenAbstract readValidation Study
In one paragraph

Article in Analytical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Céline VocatService of Clinical Pharmacology , Lausanne University Hospital and University of Lausanne , 1011 Lausanne , Switzerland.
Marielle DunandService of Clinical Pharmacology , Lausanne University Hospital and University of Lausanne , 1011 Lausanne , Switzerland.
Scott A HubersDivision of Clinical Pharmacology, Department of Medicine , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Nicolas BourdillonInstitute of Sport Sciences (ISSUL) , University of Lausanne , 1015 Lausanne , Switzerland.
Grégoire P MilletInstitute of Sport Sciences (ISSUL) , University of Lausanne , 1015 Lausanne , Switzerland.
Nancy J BrownDivision of Clinical Pharmacology, Department of Medicine , Vanderbilt University Medical Center , Nashville , Tennessee 37232 , United States.
Grégoire WuerznerService of Nephrology and Hypertension , Lausanne University Hospital and University of Lausanne , 1011 Lausanne , Switzerland.
Eric GrouzmannService of Clinical Pharmacology , Lausanne University Hospital and University of Lausanne , 1011 Lausanne , Switzerland.
Philippe J EugsterService of Clinical Pharmacology , Lausanne University Hospital and University of Lausanne , 1011 Lausanne , Switzerland.ORCID 0000-0002-0197-6318
University of Lausanne · CHVanderbilt University Medical Center · US

Funding

Cardiovascular Consequences of Peptidase InhibitionR01HL125426 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BROWN, NANCY J. · 2015 to 2019
$2.3M
NHLBI NIH HHS R01 HL125426
6 · The paper itself

Abstract

Neuropeptide Y (NPY) is a 36-amino acid peptide circulating at a subpicomolar concentration participating in multiple physiological and pathological processes. NPY is prone to peptidolysis, generating metabolites with modified affinity for the five known receptors of NPY that mediate distinct effects. It is, therefore, crucial to distinguish each metabolite to understand the multiple functions of NPY. Since immunoassays are not able to distinguish NPY from its metabolites, we have validated a microliquid chromatography tandem mass spectrometry (micro-LC-MS/MS) assay for the quantification of endogenous NPY, NPY2-36, NPY3-36, NPY1-35, and NPY3-35 in human plasma. Sample preparation relies on immunoextraction in 96-well plates, followed by solid-phase extraction prior to micro-LC-MS/MS. The LLOQ ranged from 0.03 to 0.16 pM, intra- and inter-assay precision were <27% and trueness <22%. We determined reference intervals in 155 healthy volunteers and 40 hypertensive patients. We found that NPY3-36 is the main circulating peptide in resting conditions and that NPY and catecholamines are simultaneously increased during orthostasis. We also showed that the concentrations of NPY and its metabolites are similar in healthy volunteers and hypertensive patients. NPY is the prototype peptide that circulates in concentrations expected to be beyond instrumental capacities. We have been successful in developing a high-throughput specific and sensitive assay by including a deep knowledge of the physicochemical properties of these peptides to an efficient multistep sample preparation, and a micro-LC chromatography. We believe that our methodological approach opens the possibility to selectively quantify other endogenous peptides cleaved by peptidases whose concentrations are below 1 pM.

Indexed as

Antibodies, ImmobilizedChromatography, High Pressure LiquidEquipment DesignHumansLimit of DetectionNeuropeptide YSolid Phase ExtractionTandem Mass SpectrometryAntibodies, ImmobilizedNeuropeptide Y

Identifiers

PMID31790196
PMCPMC8541045
OpenAlexW2993560375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.